Presentations from ISPOR Europe 2018

OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations.

OHE staff recently attended the ISPOR Europe 2018 conference in Barcelona. In this blog post, we share a selection of our presentations.

Budget Impact and Expenditure Caps: Potential or Pitfall? from Office of Health Economics

The debate on indication-based pricing from Office of Health Economics

What Does Patient-centred Care Mean for Medicine in the Welfare States of Europe: A Response to Peter Zweifel from Office of Health Economics

HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Health Coverage? from Office of Health Economics

Global Pharmaceutical Innovation – Too Much, Too Little or Both? from Office of Health Economics

Payment Mechanisms and handling Uncertainty from Office of Health Economics

Establishing an Aligned View of a Modern Forward-looking HTA Process from Office of Health Economics

Should Drug Prices Differ by Indication? Outlining the debate on indication-based pricing and how it has been implemented to date from Office of Health Economics

News & Insights

Latest Research & Publications

An Analysis of NICE’s Optimised Decisions from 2015 to 2024

Analysing Global Immunisation Expenditure

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

Challenges and Solutions for Budget Impact Analysis of Gene Therapies

Establishing the Economic Value of Carbon-Minimal Inhalers

The Importance of Diversity of Supply in Rare Diseases Markets

2023 OHE Annual Report to the Charity Commission

Employer Costs from Respiratory Infections

All Publications

Presentations from ISPOR Europe 2018

Related News

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Cornerstones of ‘Fair’ Drug Coverage

Establishing a Reasonable Price for an Orphan Drug

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Share on Mastodon